With almost 10 mio lives lost each year, cancer is one of the leading causes of death in the western world. We are committed to ensure that both patients with cancer and patients with benign blood disorders have access to the most effective available treatments.
Our interdisciplinary research covers the entire translational spectrum from epidemiological to experimental and clinical cancer research, often embedded in national and international collaborations. Multiple techniques are used such as whole genome sequencing, advanced flow cytometry, stem cell transplantation and cancer cytogenetics.
We are approximately 200 researchers represented by medical doctors, nurses, radiation physicists, molecular biologists, cancer geneticists and bioinformaticians within oncology, and hematology. We also collaborate with biomedical and pharmaceutical industry, and, at increasing pace, with patient advocacy groups and regulatory agencies.
Patients with sarcoma or other rare cancers often encounter lack of knowledge from others, and they often feel set aside for the more common cancers.